Pipeline

At Alfa Cytology, we are actively advancing our cutting-edge Alfa-TIL™ platform, offering a comprehensive pipeline for TIL development. This platform represents a significant leap forward in cancer immunotherapy, combining precision TIL isolation, genetic engineering, and functional validation into a streamlined, efficient service. Our Alfa-TIL™ platform is designed to harness the power of tumor-infiltrating lymphocytes (TILs) by isolating and expanding them from minimal tissue inputs, then enhancing their efficacy through genetic modification. By leveraging multi-omics profiling, we provide a deep understanding of TIL function, enabling precise optimization for preclinical testing. Whether you are looking to license our Alfa-TIL™ platform or partner for co-development, we offer flexible collaboration options to meet your unique research goals and accelerate the path from discovery to validation.

If you are interested in any of the projects, please contact us for further discussion. We eagerly anticipate the opportunity to collaborate with you.

Projects	Target	Indication	Discovery	Preclinical	IND	Phase II I	Phase II	Phase III
AlfaTIL003	To be disclosed	Solid Tumors
AlfaTIL022	To be disclosed	Solid Tumors
AlfaTIL024	To be disclosed	Solid Tumors

By engaging with our Alfa-TIL™ platform, partners gain access to a comprehensive suite of services and expertise aimed at advancing the development of next-generation TIL-based therapies. We are committed to harnessing the full potential of our platform to create immunotherapies with exceptional efficacy and precision, significantly accelerating the discovery and development of transformative cancer treatments.

Alfa Cytology's TIL pipeline is engineered to support ambitious immuno-oncology projects from concept to in vivo validation. Whether advancing novel TIL constructs, seeking functional proof-of-concept, or exploring biomarker signatures, our services are tailored to preclinical research needs. Contact us to discuss a bespoke pipeline for your TIL program and explore potential collaboration opportunities. science and collaborative innovation.